- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00954460
Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease
May 18, 2021 updated by: Shire
Multicenter Open-Label Treatment Protocol to Observe the Safety of Gene-Activated™ Human Glucocerebrosidase (GA-GCB, Velaglucerase Alfa) ERT in Newly Diagnosed or Previously Treated (With Imiglucerase) Patients With Type 1 Gaucher Disease
Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB).
Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction.
The purpose of this treatment protocol is to observe the safety of velaglucerase alfa in patients with type 1 Gaucher disease who are either treatment naive (newly diagnosed) or who are currently being treated with the Enzyme Replacement Therapy (ERT) imiglucerase.
Study Overview
Status
Approved for marketing
Conditions
Intervention / Treatment
Detailed Description
Type 1 Gaucher disease, the most common form, accounts for more than 90% of all cases of Gaucher disease and does not involve the CNS.
Typical manifestations of type 1 Gaucher disease include hepatomegaly, splenomegaly, thrombocytopenia, bleeding tendencies, anemia, hypermetabolism, skeletal pathology, growth retardation, pulmonary disease, and decreased quality of life.
Velaglucerase alfa (Gene-Activated™ human glucocerebrosidase;GA-GCB) is produced in a continuous human cell line using proprietary gene-activation technology and has an identical amino acid sequence to the naturally occurring human enzyme.
Velaglucerase alfa contains terminal mannose residues that target the enzyme to the macrophages-the primary target cells in Gaucher disease.
This treatment protocol will observe the safety of velaglucerase alfa in patients with type 1 Gaucher disease who are either treatment naive (newly diagnosed) or who are currently being treated with the Enzyme Replacement Therapy (ERT) imiglucerase.
Patients currently being treated with ERT for their Gaucher disease will receive the same number of units of velaglucerase alfa per month as their imiglucerase dose for doses between 30-120 U/kg/month.
For patients who experienced dose reductions in their imiglucerase treatment due to supply constraints the pre-reduction monthly dose may be used to determine the monthly dose of velaglucerase alfa.
Study Type
Expanded Access
Expanded Access Type
- Intermediate-size Population
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
- St Joseph's Hospital & Medical Center
-
-
California
-
Beverly Hills, California, United States, 90211-1850
- Tower Hematology Oncology
-
La Jolla, California, United States, 92093
- Rady's Children's Hospital of San Diego
-
Los Angeles, California, United States, 90027
- Southern California Permanente Medical Group
-
Sacramento, California, United States, 95815
- The Permanente Medical Group
-
Stanford, California, United States, 94305-5208
- Stanford University Medical Genetics
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Rocky Mountain Cancer Centers
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale University
-
-
Florida
-
Coral Springs, Florida, United States, 33065
- University Research Foundation for Lysosomal Storage Diseases
-
Gainesville, Florida, United States, 32605-4218
- Gainesville Hematology Oncology Associates
-
Orlando, Florida, United States, 32804-4603
- Adventis Healthcare System dba Florida Hospital
-
Palm Harbor, Florida, United States, 34685
- East Lake Oncology
-
-
Georgia
-
Decatur, Georgia, United States, 30033
- Emory Genetics
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Children's Memorial Hospital
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
Maryland
-
Annapolis, Maryland, United States, 21401
- Annapolis Oncology Center
-
Baltimore, Maryland, United States, 21215
- Sinai Hospital of Baltimore
-
-
Massachusetts
-
Shrewsbury, Massachusetts, United States, 01545
- University of Massachusetts
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Children's Hospitals and Clinics of Minnesota
-
-
Missouri
-
Kansas City, Missouri, United States, 64108-4619
- The University Research Foundation for Lysosomal Storage Diseases
-
-
New Jersey
-
Paterson, New Jersey, United States, 07503
- St. Joseph's
-
-
New York
-
Buffalo, New York, United States, 14215
- Hemophilia Center of Western New York Incorporated
-
Manhasset, New York, United States, 11030
- North Shore Hematology/Oncology - Manhasset
-
New York, New York, United States, 10016
- New York University School of Medicine
-
New York, New York, United States, 10029-6500
- Mount Sinai School of Medicine
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801-4420
- Fullerton Genetic
-
Durham, North Carolina, United States, 27710
- Duke Medical Center
-
-
Ohio
-
Akron, Ohio, United States, 44308
- Akron Children's Hospital
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908-0386
- University of Virginia Health Systems
-
Springfield, Virginia, United States, 22152
- O & O Alpan, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The patient has a documented diagnosis of type 1 Gaucher disease
- The patient is > 2 years of age
- The patient has NOT previously experienced an anaphylactic or anaphylactoid reaction to another ERT including imiglucerase
- Women of child-bearing potential must agree to use a medically acceptable method of contraception at all times during the study; and must have a negative result to a pregnancy test as required throughout their participation in the study. Male patients must use a medically acceptable method of birth control throughout their participation in the study and must report their partner's pregnancy.
- The patient is sufficiently cooperative to participate in this treatment plan as judged by the Investigator
If the patient is naïve or new to treatment, the patient has one or more of the following (in absence of the following criteria, please call the sponsor for treatment justification):
- Gaucher disease-related anemia
- Moderate splenomegaly (2 to 3 cm below the left costal margin), by palpation
- Gaucher disease-related thrombocytopenia
- Gaucher disease-related palpable enlarged liver
Exclusion Criteria: None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
August 5, 2009
First Submitted That Met QC Criteria
August 6, 2009
First Posted (Estimate)
August 7, 2009
Study Record Updates
Last Update Posted (Actual)
May 21, 2021
Last Update Submitted That Met QC Criteria
May 18, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Lipid Metabolism Disorders
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Sphingolipidoses
- Lysosomal Storage Diseases, Nervous System
- Lipidoses
- Lipid Metabolism, Inborn Errors
- Gaucher Disease
Other Study ID Numbers
- HGT-GCB-058
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gaucher Disease, Type 1
-
KemPharm Denmark A/STerminatedGaucher Disease, Type 1 | Gaucher Disease, Type 3India
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited Kingdom, United States
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited States
-
Amicus TherapeuticsCompletedGaucher Disease | Gaucher Disease, Type 1 | Type 1 Gaucher DiseaseUnited Kingdom, Israel, South Africa, United States
-
Freeline TherapeuticsRecruitingGaucher Disease, Type 1Spain, Israel, United States, United Kingdom, Brazil, Germany, Paraguay
-
CANbridge (Suzhou) Bio-pharma Co., Ltd.RecruitingGaucher Disease, Type 1 | Gaucher Disease, Type 3China
-
Genzyme, a Sanofi CompanyActive, not recruitingGaucher Disease Type 1 | Gaucher Disease Type 3Germany, United States, Japan, United Kingdom
-
Baylor Research InstituteTexas Scottish Rite Hospital for ChildrenWithdrawnGaucher Disease Type 1 | Gaucher Disease Type 3United States
-
Genzyme, a Sanofi CompanyCompletedGaucher Disease, Type 1 | Cerebroside Lipidosis Syndrome | Glucocerebrosidase Deficiency Disease | Glucosylceramide Beta-Glucosidase Deficiency Disease | Gaucher Disease, Non-Neuronopathic FormUnited States, Israel, Mexico, Russian Federation, Argentina, Italy
-
ShireCompletedGaucher DiseaseUnited States, Spain, United Kingdom, Israel
Clinical Trials on velaglucerase alfa
-
ShireQuintiles, Inc.Completed
-
TakedaActive, not recruiting
-
Shaare Zedek Medical CenterCompleted
-
Baylor Research InstituteTexas Scottish Rite Hospital for ChildrenWithdrawnGaucher Disease Type 1 | Gaucher Disease Type 3United States
-
ShireCompleted
-
Shaare Zedek Medical CenterShireCompletedGaucher Disease, Type 1
-
ShireCompletedGaucher DiseaseIsrael, Romania, Serbia
-
ShireCompletedGaucher Disease, Type 3Egypt, India, Tunisia
-
ShireCompletedGaucher Disease, Type 1Spain, Israel, United States, India, Paraguay, United Kingdom, Russian Federation, Tunisia, Argentina
-
AVROBIOWithdrawn